Drugmaker set to profit from unsafe opioid

It's not uncommon for drug companies to try to keep generic versions of their best-selling drugs off the market. But this is a story about a drug company that went to extraordinary lengths to do so, calling into question the safety of a drug it had sold for years. When its plan didn't work, the company made an unusual decision.

Comments

Popular posts from this blog

How to tip The Verge: secure email, Signal, SecureDrop, and more

The New York Attorney General’s Office will investigate the Capital One data breach

Android Pie is rolling out for the notched Motorola One